Business Description
Soligenix is a Princeton, New Jersey-based biopharmaceutical company founded in 1987 that focuses on bringing treatments to market for rare and serious medical conditions. The company is advancing several late-stage drug candidates, including a light-based therapy for a rare form of skin cancer and treatments aimed at reducing severe mouth sores in cancer patients and managing other inflammatory conditions. Through a separate arm of the business, Soligenix is also developing vaccines and countermeasures against serious public health threats, including ricin poisoning and deadly viral outbreaks such as Ebola and Marburg.
